This is part two of a two-part series examining the venture capital landscape in the life science research tools and molecular diagnostics markets. To read part one, click here.

NEW YORK (GenomeWeb News) – Despite the recently soured economy, venture capitalists have remained relatively optimistic about investment opportunities in the life science research tools and molecular diagnostics sectors, according to industry insiders.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.